When does Abbott report earnings?
Abbott Laboratories · end-of-day data as of Nov 13, 2026
- PT$121.32 +11.8%
- ConsensusBuy · 28
- MAs4 of 4
- MA20×50Golden 7d ago
- Sector▲ +15.9%
- Earnings in76d
- P/E40.2x
- RSI54
- Support-1.6%
- Resistance+2.2%
- Off 52w high-17.8%
- Volume0.7x
- Bollingerupper half
- News1.00
- Trendsideways
- 52w range$82–$132
- ATR+2.7%
- Off ATH-23.9%
- P/E vs own+25.6%
- P/E vs sector+24.8%
- Insiders-$46.61M
- MACD-0.08
Updates with the 15-min delayed price. Not a forecast or investment advice.
![]()
The stock around its reports
Last close $108.52 · -3.0% over 2y · E earnings · D dividend · S split · A analyst rating change
Quarterly results
Q3 FY2026: Revenue +14.5% year over year, free cash flow 9.4% of revenue, operating margin 11.3%.
| Q3 FY2026 | Sep 30, 2026 | $13.01B | 0.53 | $1.22B | 57.1% | 11.3% | 7.1% |
| Q2 FY2026 | Jun 30, 2026 | $12.59B | 0.53 | — | 58.0% | 14.2% | 7.4% |
| Q1 FY2026 | Mar 31, 2026 | $11.16B | 0.62 | $916M | 56.3% | 16.5% | 9.6% |
| Q4 FY2025 | Dec 31, 2025 | $11.46B | 1.02 | $2.63B | 57.0% | 19.6% | 15.5% |
| Q3 FY2025 | Sep 30, 2025 | $11.37B | 0.94 | $2.29B | 55.7% | 18.1% | 14.5% |
| Q2 FY2025 | Jun 30, 2025 | $11.14B | 1.01 | $1.54B | 56.4% | 18.4% | 16.0% |
| Q1 FY2025 | Mar 31, 2025 | $10.36B | 0.76 | $933M | 52.6% | 16.3% | 12.8% |
| Q4 FY2024 | Dec 31, 2024 | $10.97B | 5.27 | $2.15B | 51.0% | 18.1% | 84.1% |